Urea Cycle Disorders Treatment Market Report 2026
Global Outlook – By Treatment (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments), By Enzyme Deficiency (Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS–), By Route of Administration (Oral, Injectables), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2030
Urea Cycle Disorders Treatment Market Overview
• Urea Cycle Disorders Treatment market size has reached to $1.37 billion in 2025 • Expected to grow to $1.71 billion in 2030 at a compound annual growth rate (CAGR) of 4.6% • Growth Driver: Surging Chronic Kidney Disorder Cases Fuels Urea Cycle Disorders Treatment Market Growth • Market Trend: Strategic Partnerships Drive Innovative Therapies In The Urea Cycle Disorder Treatment Industry • North America was the largest region in 2025.What Is Covered Under Urea Cycle Disorders Treatment Market?
Urea cycle disorder treatment refers to managing rare genetic diseases where the body lacks the enzymes necessary to break down ammonia, causing it to build up and potentially be poisonous. The objective of urea cycle disorder treatment is to reduce blood ammonia levels. The main types of treatment for urea cycle disorders are amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, and others. Amino acid supplements refer to supplements that include one or more of the nine necessary amino acids that the body cannot create on its own. The distinct types of enzyme deficiency are included, such as OTC (ornithine transcarbamylase), AS (argininosuccinate synthetase) (citrullinemia), AG (arginase), AL (argininosuccinate lyase), and CPS1 (carbamoyl phosphate synthase). These are administered through oral and injectable modes and are sold through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
What Is The Urea Cycle Disorders Treatment Market Size and Share 2026?
The urea cycle disorders treatment market size has grown steadily in recent years. It will grow from $1.37 billion in 2025 to $1.43 billion in 2026 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to lack of awareness about ucd, limited treatment options, low patient diagnosis rates, high treatment costs, dependence on hospital-based care.What Is The Urea Cycle Disorders Treatment Market Growth Forecast?
The urea cycle disorders treatment market size is expected to see steady growth in the next few years. It will grow to $1.71 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growth in gene therapy research, rising adoption of precision medicine, technological advancements in ammonia monitoring, increasing pediatric patient focus, expansion of home healthcare services. Major trends in the forecast period include personalized ucd therapy development, improved ammonia scavenger formulations, enzyme replacement therapy advancements, pediatric-focused treatment innovations, home-based and remote monitoring solutions.
Global Urea Cycle Disorders Treatment Market Segmentation
1) By Treatment: Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments 2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1) 3) By Route of Administration: Oral, Injectables 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Amino Acid Supplements: Arginine Supplements, Citrulline Supplements, Other Essential Amino Acids 2) By Sodium Phenylbutyrate: Powder Form, Tablet Form 3) By Glycerol Phenylbutyrate: Oral Solutions, Other Forms 4) By Sodium Benzoate: Intravenous Solutions, Oral Formulations 5) By Other Treatments: Liver Transplantation, Dietary Modifications, Enzyme Replacement Therapy, Other Supportive TherapiesWhat Is The Driver Of The Urea Cycle Disorders Treatment Market?
The rising number of chronic kidney disorder cases is expected to propel the growth of the urea cycle disorders treatment market going forward. Chronic kidney disease (CKD) is a long-term condition characterized by the gradual loss of kidney function over time. Chronic kidney disorder utilizes urea cycle disorder treatment to manage metabolic waste, particularly elevated levels of urea, as impaired kidney function hinders proper waste excretion. For instance, in November 2023, according to Kidney Care UK, a UK-based kidney patient support charity, approximately 7.2 million individuals are estimated to have chronic kidney disease (CKD) stages 1–5, with around 3.5 million people in the UK experiencing the later stages of CKD (stages 3-5), during which symptoms are expected to become progressively challenging to control. Therefore, the rising number of chronic kidney disorder cases is driving the growth of the urea cycle disorders treatment industry.Key Players In The Global Urea Cycle Disorders Treatment Market
Major companies operating in the urea cycle disorders treatment market are Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding, Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics Inc., Orpharma Pty Ltd., Horizon Therapeutics Plc, Synlogic, Amicus Therapeutics, Sobi, PTC Therapeutics, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Protalix BioTherapeutics, Erytech Pharma, Relief Therapeutics Holding AG, Selecta Biosciences Inc., Argenx SE, Dynacure SA, Inventiva SA
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Urea Cycle Disorders Treatment Market Trends and Insights
Major companies operating in the urea cycle disorder treatment industry are adopting a strategic partnership approach to innovative therapies and improving disease management. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in June 2024, Orsini Specialty Pharmacy, a US-based personalized care and medications provider, and Zevra Therapeutics Inc., a US-based rare disease therapeutics company, announced that Orsini is the pharmacy partner for OLPRUVA (sodium phenylbutyrate) oral suspension. OLPRUVA is a prescription medication used in combination with certain therapies, including dietary changes, for the long-term management of urea cycle disorders (UCDs) in specific adult and pediatric patients with deficiencies in carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).What Are Latest Mergers And Acquisitions In The Urea Cycle Disorders Treatment Market?
In November 2023, Zevra Therapeutics Inc., a US-based rare disease therapeutics company, acquired Acer Therapeutics Inc. for $91 million. Through this acquisition, Zevra has access to rare disease assets, including Edsivo, which is presently being examined in Phase III trials for vascular Ehlers-Danlos syndrome, and Olpruva, which the Food and Drug Administration (FDA) has approved for the treatment of certain urea cycle diseases. It gives Zevra its size and diversifies its revenue stream as it enters the commercial arena. Acer Therapeutics Inc. is a US-based pharmaceutical company that provides treatment for urea cycle disorders.
Regional Insights
North America was the largest region in the urea cycle disorders treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Urea Cycle Disorders Treatment Market?
The urea cycle disorders treatment market includes revenues earned by entities by hemodialysis, dietary management, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The urea cycle disorders treatment market also includes sales of arginine, sodium phenylacetate, sodium benzoate, and carglumic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Urea Cycle Disorders Treatment Market Report 2026?
The urea cycle disorders treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the urea cycle disorders treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Urea Cycle Disorders Treatment Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $1.43 billion |
| Revenue Forecast In 2030 | $1.71 billion |
| Growth Rate | CAGR of 3.8% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Treatment, Enzyme Deficiency, Route of Administration, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding, Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics Inc., Orpharma Pty Ltd., Horizon Therapeutics Plc, Synlogic, Amicus Therapeutics, Sobi, PTC Therapeutics, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Protalix BioTherapeutics, Erytech Pharma, Relief Therapeutics Holding AG, Selecta Biosciences Inc., Argenx SE, Dynacure SA, Inventiva SA |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |